Innoviva is a biopharmaceutical company with a royalties portfolio including respiratory assets from GSK, and the Innoviva Specialty Therapeutics platform developing critical care and infectious disease treatments: GIAPREZA (angiotensin II) for septic shock, XACDURO (sulbactam/durlobactam) for bacterial pneumonia, XERAVA (eravacycline) for intra-abdominal infections, ZEVTERA (ceftobiprole) antibiotic, and NUZOLVENCE (zoliflodacin).
